Endothelial cells could be targeted to restore lung function in COVID-19 patients, suggests study
FirstpostThe study authors also said that drugs targeting endothelial activation should be used to control inflammation and coagulopathy associated with COVID-19 COVID-19 is primarily a respiratory disease that spreads through droplets. Now, a group of researchers at the Stony Brook University, US, state that endothelial cells don’t have ACE2 receptors and hence SARS-CoV-2 does not infect these cells directly. However, since endothelial damage is seen in COVID-19 patients, the authors suggest that the virus is indirectly affecting endothelial cells. Indirect infection of endothelial cells For the study, the researchers examined SARS-CoV-2 infection in the endothelial cells obtained from the lungs, kidneys, heart, brain and umbilical veins. Targeting the endothelial cells Because the endothelial cells are not actually infected by SARS-CoV-2, drug therapies against the infection would be useless in the treatment of endothelial inflammation in coronavirus patients.